A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh
Safety and efficacy of paromomycin/ miltefosine/ liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study
Jorge Alvar, médico: «Nuestro modelo funciona. Hemos desarrollado 12 medicamentos y tendremos otros 15 en 2030»
Interruption of mother-to-child transmission and detection and treatment of children of infected mothers as a contribution to eradicate Chagas disease in Europe
Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action
In vitro susceptibility to miltefosine of Leishmania infantum (syn. L. chagasi) isolates from different geographical areas in Brazil